ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Type 1 Natural Killer T-cells: Key Mediators of Ischemia- Reperfusion Injury in Hepatic Steatosis

J. R. Liggett1, J. Kang1, K. Loh1, K. Oza1, Y. Cui1, D. Kwon2, H. Li3, B. Kallakury2, T. Fishbein1, W. Cui1, K. Khalid1, A. H. Kroemer1

1MedStar Georgetown Transplant Institute, Washington, DC, 2Pathology, MedStar Georgetown University Hospital, Washington, DC, 3Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC

Meeting: 2022 American Transplant Congress

Abstract number: 655

Keywords: Ischemia, Mice

Topic: Basic Science » Basic Science » 14 - Ischemia Reperfusion

Session Information

Session Name: Ischemia Reperfusion

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Hepatic ischemia-reperfusion injury (IRI) poses a significant risk in liver transplantation and hepatic resection and is further exacerbated by hepatic steatosis. Type 1 Natural Killer T-cells (iNKT cells) play a critical role in hepatic IRI. In this study, we evaluate the role of iNKT in hepatic steatosis complicated IRI, an area that is largely understudied.

*Methods: C57BL/6 mice were placed on a normal diet (ND) or high-fat diet (HFD) composed of 20% and 60% fat, respectively. Mice were subjected to sham operations versus partial hepatic ischemia in the left and median lobes for 45 minutes, which simulated the average warm ischemia time during transplantation. Reperfusion occurred for 24 hours post-procedure. A subset of mice from both groups was allocated to receive oral N-Acetylcysteine (po-NAC) supplementation. NAC was administered as a 1% solution in drinking water ad libitum.

*Results: IRI in HFD mice was exacerbated when compared to ND mice. This was evident in the evaluation of serum alanine aminotransferase (ALT) levels, Suzuki scoring of H&E stained sections, and influx of neutrophils (Gr-1) and macrophages (CD-68) on stained sections. Polychromatic flow cytometry demonstrated a pronounced increase in CD45+CD3+NK1.1+ iNKT cells when compared to ND IRI and HFD sham mice. This was verified by measuring ex vivo cytokine expression in the HFD and ND mice following IRI, proving higher INF-γ expression in the HFD mice. We hypothesized this was secondary to increased activation of iNKT by phospholipid ligands. To test this, we performed a lipidomic analysis of hepatic tissue, which revealed a higher composition of triacylglycerols (TAG) and phospholipids (PL) in the HFD mice. Since NAC can reduce hepatic steatosis, we then examined the reaction to IRI in HFD+po-NAC mice. Interestingly, not only did HFD+po-NAC mice have less hepatic steatosis as evident on H&E sections, but also had a vast reduction in IRI. Type 1 NKT cells were largely reduced in these mice and consistent with ND Sham mice. This was consistent with lipidomic evaluation showing a decrease in TAG and PL, which we postulate resulted in fewer iNKT cell-activating ligands.

*Conclusions: Hepatic Steatosis results in profound IRI via iNKT cell-dependent mechanism secondary to PL activation and is ameliorated by po-NAC. This provides the foundation for further investigation to prevent IRI in liver transplantation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Liggett JR, Kang J, Loh K, Oza K, Cui Y, Kwon D, Li H, Kallakury B, Fishbein T, Cui W, Khalid K, Kroemer AH. Type 1 Natural Killer T-cells: Key Mediators of Ischemia- Reperfusion Injury in Hepatic Steatosis [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/type-1-natural-killer-t-cells-key-mediators-of-ischemia-reperfusion-injury-in-hepatic-steatosis/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences